About Us
NEXT Oncology KMU JAPAN and Early Phase 1 Drug Development Service, Department of New Experimental Therapeutics at Kansai Medical University Hospital (KMUH) conducts phase I trials of promising new drugs in patients with advanced solid tumors.
We run broad phase I clinical trials across disease types and molecular targets by utilizing rapid study site activation based on fast IRB, study contract and dedicated early phase 1 drug development service. We have also officially designated as “Preferred Oncology Phase 1 Site” from fair number of global pharmaceutical sponsors since 2025.
